Duweb Amira, Schmiech Michael, Ulrich Judith, Abdel-Kahaar Emaad, Pfeiffer Maximilian, El Gaafary Menna, Barth Holger, Simmet Thomas, Syrovets Tatiana
Institute of Experimental and Clinical Pharmacology, Toxicology, and Pharmacology of Natural Products, University of Ulm Medical Center, Ulm, Germany; Department of Pharmacology, Faculty of Medicine, University of Tripoli, Tripoli, Libya.
Institute of Experimental and Clinical Pharmacology, Toxicology, and Pharmacology of Natural Products, University of Ulm Medical Center, Ulm, Germany.
Biomed Pharmacother. 2025 May;186:118009. doi: 10.1016/j.biopha.2025.118009. Epub 2025 Mar 28.
Chronic inflammatory disorders represent one of the predominant healthcare burdens. There is evidence that the oleogum resin from Boswellia serrata trees can downmodulate pro-inflammatory processes. Lipid micellar preparations of Boswellia serrata have been introduced to the market to overcome the low bioavailability of nonformulated Boswellia oleogum resin preparations. In this study, we aimed to compare the anti-inflammatory effects of two different Boswellia serrata nutraceuticals: the native, nonformulated Biotikon® BS-85 and the micellar Boswellia-Loges®. We have previously shown that single oral administration of 800 mg of either formulation reduces the release of proinflammatory cytokines TNF-α, IL-1β, and IL-6 by LPS-activated blood of donors. Here we show that under the same conditions, the production of IL-17A was increased by the nonformulated, native extract of Boswellia serrata oleogum resin. In vitro, the nonformulated but not the micellar formulation of Boswellia serrata oleogum resin decreased the release of IFN-γ, TNF-α, and IL-2 by TCR-activated lymphocytes. Both formulations as well as the bioactive principles boswellic acids lowered NF-κB activity in TCR-activated T lymphocytes. Similarly, both Boswellia serrata formulations and boswellic acids reduced NFAT activity in TCR-activated T lymphocytes. The nonformulated Boswellia serrata extract exhibited higher inhibitory activity on the release of T-cell cytokines. The results suggest that nutraceuticals containing the nonformulated oleogum extract of Boswellia serrata might be more effective in hampering chronic inflammatory disorders characterized by increased activity of T cells than the micellar formulations.
慢性炎症性疾病是主要的医疗负担之一。有证据表明，乳香树的油胶树脂可以下调促炎过程。为了克服未配制的乳香油胶树脂制剂生物利用度低的问题，乳香的脂质胶束制剂已投放市场。在本研究中，我们旨在比较两种不同的乳香营养保健品的抗炎效果：天然的、未配制的Biotikon® BS-85和胶束化的Boswellia-Loges®。我们之前已经表明，单次口服800毫克这两种制剂中的任何一种，均可降低脂多糖激活的供体血液中促炎细胞因子TNF-α、IL-1β和IL-6的释放。在此我们表明，在相同条件下，未配制的天然乳香油胶树脂提取物可增加IL-17A的产生。在体外，未配制的而非胶束化的乳香油胶树脂制剂可降低T细胞受体激活的淋巴细胞释放IFN-γ、TNF-α和IL-2。两种制剂以及生物活性成分乳香酸均可降低T细胞受体激活的T淋巴细胞中的NF-κB活性。同样地，两种乳香制剂和乳香酸均可降低T细胞受体激活的T淋巴细胞中的NFAT活性。未配制的乳香提取物对T细胞细胞因子的释放表现出更高的抑制活性。结果表明，含有未配制的乳香油胶提取物的营养保健品在抑制以T细胞活性增加为特征的慢性炎症性疾病方面可能比胶束制剂更有效。
